IPM Take
The obesity debate is changing. For years, access to GLP-1 therapies was constrained by cost, supply shortages and the reality that many patients were reluctant to start injectable treatment. Oral GLP-1s could remove one of those barriers. That creates a new policy challenge. If obesity treatment becomes easier to prescribe and easier to take, demand may increase dramatically. The next debate may not be about efficacy. It may be about who pays, who qualifies and whether health systems can afford obesity treatment at scale.
Executive Summary
Novo Nordisk announced that oral Wegovy has surpassed 3 million prescriptions in the United States since launching in January 2026, making it one of the fastest pharmaceutical launches by prescription volume in recent years. More than 80% of prescriptions were reportedly written for patients new to GLP-1 therapy, suggesting oral formulations may be expanding access rather than simply replacing injectable treatments. At the same time, the European Medicines Agency has recommended approval of oral Wegovy as the first oral GLP-1 therapy for weight management in Europe. Together, these developments signal a potential shift in obesity treatment from specialist intervention towards broader primary care adoption.
Why it matters
- Policymakers: Rising demand for obesity medicines may intensify debates around reimbursement, eligibility criteria and long-term affordability.
- Health systems: Oral therapies could expand access through primary care, telehealth and community-based treatment pathways.
- Payers: Large eligible populations may create substantial budget pressures if uptake accelerates.
- Industry / innovation partners: The emergence of multiple oral GLP-1 competitors could reshape obesity treatment markets and broaden patient reach.
- Patients: Oral formulations may offer a more acceptable treatment option for individuals unwilling or unable to use injections.
Obesity medicines have spent the past few years dominating headlines, investor calls and conference agendas.
What is happening now may be more significant.
The arrival of effective oral GLP-1s raises the prospect that obesity treatment could move beyond specialist clinics and become part of everyday healthcare.
Novo Nordisk’s announcement that oral Wegovy has already surpassed 3 million prescriptions in the United States provides an early glimpse of what that future could look like.
The number itself is impressive.
The more important detail may be who is receiving the prescriptions.
According to Novo Nordisk, more than 80% of oral Wegovy prescriptions have been written for people who were not previously using GLP-1 therapies.
That suggests the pill is not simply replacing injections.
Instead, it may be bringing entirely new groups of patients into treatment. People who were hesitant about injections, reluctant to attend specialist clinics or unsure about starting long-term therapy may view a daily pill very differently. What once felt like a specialist intervention can begin to look like a familiar part of routine healthcare.
In that sense, the significance of oral GLP-1s may extend beyond convenience. They have the potential to change how obesity treatment is perceived, prescribed and accessed.
Historically, obesity treatment has faced several barriers simultaneously.
Many patients did not qualify for reimbursement. Others faced stigma. Some were reluctant to self-inject. Healthcare systems often lacked dedicated obesity pathways altogether.
Oral GLP-1s do not solve every problem.
But they remove one important barrier.
The treatment increasingly resembles how health systems already manage other chronic diseases.
Take a pill. Monitor outcomes. Adjust treatment.
That seemingly small change could have major consequences.
The European Medicines Agency recently recommended approval of oral Wegovy, positioning it to become Europe’s first oral GLP-1 therapy for weight management. Meanwhile, Eli Lilly’s Foundayo and other oral candidates are rapidly advancing through global markets.
Competition is no longer centred on efficacy alone.
The leading products are already delivering substantial weight loss.
The next battleground is practical implementation.
How many patients can health systems realistically support?
Will obesity medicines remain concentrated in specialist services, or become part of routine primary care?
And what happens to healthcare budgets if uptake expands beyond today’s relatively small treated population?
Those questions are becoming harder to ignore as oral GLP-1s move closer to mainstream use.
Current estimates suggest that more than 120 million Americans could potentially qualify for anti-obesity medicines under existing clinical criteria.
Most are not receiving treatment.
If oral therapies significantly increase uptake, payers may face difficult decisions about eligibility thresholds, duration of therapy and funding priorities.
For industry, this may represent the next major phase of the GLP-1 revolution.
The first phase proved the medicines work.
The second phase asks whether health systems can actually deliver them at population scale.
For IPM, that is where the most important policy debate begins.
The future of obesity treatment may depend less on scientific innovation and more on implementation, affordability and access.
